Technical analysis of Mereo BioPharma Group plc (MREO): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.
Price Performance
| 1 month | -15.02% |
| 3 months | -14.03% |
| Year-to-date | -36.17% |
| 1 year | -84.62% |
| 3 years | -81.78% |
| 5 years | -89.92% |
52-Week Range
| 52-week High | $2.37 |
| 52-week Low | $0.20 |
| Avg Volume (90d) | 4.5M |
Technical Indicators
| SMA 50 | $0.30 |
| SMA 200 | $0.52 |
| Beta | 0.38 |
| 30-day Volatility (annualised) | 80.3% |
| Price vs SMA 50 | -9.9% |
| Price vs SMA 200 | -48.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.90 | |
| 2025-11 | $1.87 | -1.6% |
| 2025-12 | $0.42 | -77.7% |
| 2026-01 | $0.44 | +5.6% |
| 2026-02 | $0.37 | -15.8% |
| 2026-03 | $0.33 | -11.0% |
| 2026-04 | $0.27 | -18.7% |
| 2026-05 | $0.34 | +28.2% |
| 2026-06 | $0.32 | -7.6% |
| 2026-07 | $0.34 | +7.9% |
| 2026-08 | $0.27 | -22.1% |
| 2026-09 | $0.27 | -0.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $0.27 |
| Market Cap | $42M |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 1.44 |
| EV / EBITDA | -0.33 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 5.88 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -8.98 |